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Background: Persistent atrial fibrillation frequently shows multiple different electrophysiological mechanisms of
induction. This heterogeneity causes a low success rate of single procedures of ablation and a high incidence of
recurrence. Surgical ablation through bilateral thoracotomy demonstrates better results after a single procedure.
Prospective observational studies in inhomogeneous populations without control groups report a remarkable 90%
of success with hybrid or staged procedures of surgical ablation coupled with catheter ablation. In this trial, we will
examine the hypothesis that a staged approach involving initial minimally invasive surgical ablation of persistent
atrial fibrillation, followed by a second percutaneous procedure in case of recurrence, has a higher success rate than
repeated percutaneous procedures.
Methods/Design: This is a controlled (2:1) randomized trial comparing use of a percutaneous catheter with minimally
invasive transthoracic surgical ablation of persistent atrial fibrillation. The inclusion and exclusion criteria, definitions, and
treatment protocols are those reported by the 2012 Expert Consensus Statement on catheter and surgical ablation of
atrial fibrillation. Patients will be randomized to either percutaneous catheter (n = 100) or surgical (n = 50) ablation as the
first procedure. After 3 months, they are re-evaluated, according to the same guidelines, and receive a second procedure
if necessary. Crossover will be allowed and data analyzed on an “intention-to-treat” basis. Primary outcomes are the
incidence of sinus rhythm at 6 and 12 months and the proportions of patients requiring a second procedure.
Discussion: The use of a staged strategy combining surgical and percutaneous approaches might be more favorable
in treatment of persistent atrial fibrillation than the controversial single percutaneous ablation.
Trial registration: ISRCTN08035058 Reg 06.20.2013
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Persistent atrial fibrillation (PeAF) is defined as episodes
of atrial fibrillation (AF) lasting more than 7 days or re-
quiring an electric or pharmacologic cardioversion to
restore the sinus rhythm (SR) [1]. PeAF is frequently
caused by different coexistent electrophysiological mech-
anisms of induction [2]. This complex origin frequently
requires the use of a combination of ablation techniques
to achieve acceptable results. Indeed, pulmonary vein* Correspondence: claudio.pragliola@libero.it
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unless otherwise stated.isolation (PVI) [3] and the ablation of complex frac-
tioned atrial electrograms (CFAEs) [4] did not result in
satisfactory results when used separately during percu-
taneous catheter ablation procedures (PCAs), whereas
the rate of success increased to 74% after combining the
two techniques and was 88% when ablation was repeated
after 3 months [5]. The evaluation of treatment for PeAF
is further complicated by the small number of patients
with PeAf included in controlled trials [6]. Similar out-
comes are observed for the surgical treatment of PeAF.
For example, in the FAST trial (atrial fibrillation catheter
ablation versus surgical ablation treatment) [7], surgical ab-
lation achieved better results (65% versus 36%; P = 0.0022)
than PCA in complex patients, whereas this trend was notl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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those randomized.
Regardless of the mechanism involved, the majority of
the sites of origin of PeAF are located in the posterior
part of the left atrium, as this portion is easily encom-
passed by the box lesions created by surgical ablations
[8]. As such, a staged approach may be a more suitable
strategy, with use of percutaneous endocardial tech-
niques only in case of failure of the surgical procedures.
Recently, Pison [9] obtained a success rate of 90% in
PeAf with a hybrid approach involving bilateral minimal
surgical access and PCA. In this series, only 23% of the
lines created surgically were not transmural, and 88% of
the patients had the AF terminated by a posterior left
atrial isolation. Comparable results were reported with
staged [10] approaches of thoracoscopy or transabdom-
inal pericardial [11] access and PCA.
In the present trial, we examine the hypothesis that a
staged approach involving minimally invasive surgical
ablation of persistent atrial fibrillation, followed by a sec-
ond percutaneous procedure in cases of recurrence, will
have a success rate at 12 months higher than repeated
percutaneous procedures. According to the recently pub-
lished European guidelines on surgical ablation of AF
alone, we will select patients with a class IIb indication to
surgery and use the class I bipolar radiofrequency as the
energy source for the ablation [12].
Methods
The overall hypothesis of this study is that an initial sur-
gical procedure has a higher probability of success than
an initial percutaneous ablation, and therefore, fewer
patients will be submitted to a second ablation. The pro-
posed therapies are currently accepted and considered
Class II indications in the current European Society of
Cardiology [13] and European Association of Cardio-
thoracic Surgery [12] guidelines for the treatment of
PeAf. As such, their comparison complies with the
Declaration of Helsinki for the Ethical Principles of Med-
ical Research in human subjects. The Ethics Committee
of the University of Magna Grecia in Catanzaro (Italy)
gave full approval to the study without conditions. No ex-
ternal financial support exists. Full reimbursement of the
cost of the therapies has already been granted by the Italian
National Health System.
All participants will be required to sign an informed
consent to adhere to the study. The Surgical Staged Ap-
proach (SSA) strategy consists of an initial minimally
invasive surgical ablation, followed by a percutaneous
catheter ablation if necessary. To avoid any possible bias
introduced by the difference in surgical techniques, we
will use only the bipolar radiofrequency using the Estech
cobra fusion ablator (Estech is a Market brand of Atricure
Inc West Chester 45069 Ohio USA) introduced through aright minimal thoracotomy. The control group will receive
the current standard strategy of PCA. In the case of recur-
rence of the AF, the second procedure will be either per-
cutaneous or surgical. The inclusion criteria and the
protocols for managing the pharmacologic and anticoagu-
lant therapy, the description of the surgical approach, and
the technique of the percutaneous ablation are those indi-
cated by the 2012 HRS/EHRA/ECAS expert consensus
statement on catheter and surgical ablation of AF [12] and
the European Guidelines for the treatment of lone AF [13].
Inclusion criteria
 Patient age ≥18 years.
 Patients with persistent AF defined as at least one
sustained episode lasting more than 7 days in the
last 12 months.
 Patients with symptomatic AF that is refractory to
at least one antiarrhythmic medication; symptomatic
patients are those who have been aware of their AF
at any time within the last 5 years before enrolment.
Symptoms may include, but are not restricted to,
palpitations, shortness of breath, chest pain, fatigue,
left ventricular dysfunction, or other symptoms, or
any combination of these.
 At least one episode of persistent AF must have been
documented by ECG, Holter, loop recorder, telemetry,
transtelephonic monitor, or implantable device within
last 2 years of enrollment in this investigation.
 Patients must be able and willing to provide written
informed consent to participate in this investigation.
 Patients must be willing and able to comply with all
periablation and follow-up requirements.
Exclusion criteria
 Patients with paroxysmal AF, defined as a sustained
episode lasting <7 days.
 Patients with long-standing persistent AF lasting
>1 year.
 Patients for whom cardioversion or sinus rhythm
will never be attempted/pursued.
 Patients with AF secondary to a reversible cause.
 Patients with contraindications to systemic
anticoagulation.
 Patients with left atrial size ≥55 mm (2-dimensional
echocardiography, parasternal long-axis view).




All antiarrhythmic drugs will be discontinued 5 half-
lives before the procedure. In exceptional cases requiring
Table 1 Anticipated results for different success rates of
first PCA procedure
% of SR in the PCA group after first
procedure
35% 45% 50%
χ2 test for first procedure P < 0.0001 P = 0.007 P = 0.03
Power of the test 99% 84% 65%
Strength of association
Relative risk 2.2 1.8 1.66
95% confidence interval 1.4 to 3.4 1.2 to 2.9 1.0 to 2.6
Odds ratio 4.3 2.9 2.33
95% confidence interval 2.1 to 9.0 1.4 to 5.9 1.1 to 4.7
Difference between proportions
Fraction of second procedures in the
two groups
0.65-0.30 0.55-0.30 0.50-0.30
Difference between fractions 0.35 0.25 0.2
95% confidence interval of difference 0.1 to 0.5 0.1 to 0.4 0.0 to 0.3
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toms, this will be managed with intravenous esmolol. Ami-
odarone requires at least 8 weeks of suspension.
Anticoagulant therapy
Patients receiving warfarin will stop the medication and
switch to LMW heparin, which will be maintained dur-
ing the procedure but which can be controlled in case of
major bleeding. The same applies to patients receiving
apixaban, dabigatran, or rivaroxaban, to control the si-
lent thromboembolism described during the creation of
endocardial lesions [14]. If the patient is taking only
aspirin, it need not be discontinued.
All patients will receive preoperative TEE echocardio-
grams to rule out the presence of left atrial thrombi and
to determine the size, morphology, and flow pattern in
the left atrial appendage.
Staged surgical ablation group
Fifty patients will be randomized to surgical ablation of
AF. The ablation procedure will be performed with the use
of Estech cobra fusion, according to the manufacturer’s in-
structions and to the commonly described techniques
[10,12,15]. Up to three applications will be allowed to ab-
late the left atrial box. Bidirectional block will be checked,
and reasons for not obtaining it will be noted. Inducibility
of AF at the end of the procedure will be recorded. Cardio-
version will be allowed to restore SR. At the end of the
procedure, the patient will be awakened and transferred to
the ward. An interval of 3 months will be allowed after the
initial ablation procedure, as per the Heart and Rhythm
European Society Association/European Heart Rhythm
Association/European Cardiac Arrhythmia Society expert
consensus statement [13]. During this period, the recur-
rences of AF, atrial tachycardias, and atrial flutter will not
be counted toward the primary or secondary end points.
Antiarrhythmic medications may be continued for the first
3 months to avoid early recurrences. At 3 months, they
must be stopped to assess recurrences. For patients con-
tinuing to have recurrence controlled by the therapy, it will
be left to the preference of the investigator to continue the
medical therapy or to refer the patient for a PCA.
Percutaneous catheter ablation group
One hundred patients will be randomized to PCA and
treated according to the protocol of the referring center. In
all cases, complete PVI must be at least attempted and
confirmed by bidirectional block. The referring investigator
can then add any of the current methods of PeAF treat-
ment, including substrate modification with the infusion of
isoproterenol to uncover non-PVI triggers and CFAE.
Lines can be drawn at the discretion of the investigators.
Inducibility of AF at the end of the procedure will be re-
corded. Cardioversion will be allowed to restore SR.After the 3-month blanking period, it will be left to
the investigator’s preference to refer the patients with
PeAF recurrence to a second PCA procedure, surgical
ablation, or switch to a rate-control approach. The latter
will be counted as a failed repeated procedure.
Assessment of recurrence
The recurrence will be assessed by clinical follow-up at 1,
3, 6, 9, and 12 months with 12-lead ECG+ 24 Holter moni-
toring. Transthoracic echocardiography will be also per-
formed to record the presence of an atrial contraction in
case of sinus rhythm. Quality of life will be assessed by a
modified 36-item Short Form Health Survey and the Euro
5D questionnaire. The primary outcomes include the
freedom from AF at 12 months, as detected by a 12-
lead ECG and a 24-hour Holter examination after 3, 6,
and 9 months of follow-up, and the occurrence of a
second ablation procedure. The secondary outcomes in-
clude the duration of the procedures, freedom from any
documented atrial arrhythmia, incidence of procedural
complications, any late complication related to the pro-
cedures, and quality of life.
Statistical analysis
Randomization will be performed by using currently
available computer software. Sample size is based on the
hypothesis that the success rate of the first procedure
will be approximately 70% for the surgical cases and 35%
to 40% for the PCA cases. At the end of the interven-
tions, the number of patients in SR should be equivalent
in the two groups, whereas the proportions of those sub-
mitted to a second procedure, either percutaneous or
surgical, should differ significantly. Variables will be ana-
lyzed with an intention-to-treat method. The three pos-
sible results of this study are described in Table 1. A
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the power of the test is 98% is shown in Figure 1. Data
will be expressed as mean ± SD and 95% confidence
limits, as appropriate. Comparisons between patient
groups will be performed with the Mann–Whitney test
for continuous variables and the χ2 test for categoric
variables. The z test and the odds ratio will be used
for differences between proportions of patients receiving
repeated procedures in the two groups. A value of P < 0.05
will be considered statistically significant. Time-to-event
distributions will be estimated by the Kaplan-Meier
method and compared with the log-rank test. The Cox
proportional hazards model will be used to identify inde-
pendent risk factors for recurrences. Stepwise selectionFigure 1 Flow chart of the study.procedure will be adopted. A value of P < 0.05 will be con-
sidered significant for variable entry for stepwise selection.
Analyses are performed with the SPSS 18.0 software pack-
age (SPSS, Inc, Chicago, IL, USA).
Discussion
PeAf is more complex to treat than the simple paroxys-
mal AF. Several different percutaneous and surgical
techniques have been proposed for its treatment, owing
to the difficulties in the standardization of the ablation
procedures. In addition, many reports dealing with the
ablation of PeAF also include patients affected by parox-
ysmal and permanent fibrillation, which introduces a
considerable selection bias.
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involved in ablating the PeAF, including the following:
(a) identifying the mechanism; (b) locating the source;
(c) reaching the ablation area; (d) choosing the lesion
set; and (e) consistently obtaining transmural lesions. As
PeAf shows heterogeneity in its mechanism of origin, a
simple PVI has unpredictable results. Thus, other tech-
niques such as CFAE ablation and linear ablations, with
or without substrate control, have been developed to in-
crease the percentages of termination of the arrhythmia.
Once the arrhythmia has been ablated, it can also recur
in other parts of the atrium with a different mechanism,
causing a high percentage of recurrent fibrillation. Re-
cently, focal ablation and the rotor modulation tech-
nique (FIRM) [16] have shown promising results in a
limited number of cases. Surgical ablations that de-
connect a large part of the posterior left atrium, where
many of the sources of the PeAF are located, have also
become increasing used owing to their simple approach.
Conversely, surgical procedures also are difficult to evalu-
ate, and numerous observational studies of mixed popula-
tions without controls used different sources of energy and
line combinations [15,17,18].
The FAST trial [7] was the first to compare the surgi-
cal and the percutaneous approaches, in which patients
randomized to surgery had a higher rate of termination
of the arrhythmia. However, their results were compro-
mised by the incidence of complications. Many of these
complications (pneumothorax, rib fracture) could be
easily avoided by careful analysis of the results and by
experience, which eventually results in an equivalent rate
of complications between the two experiment groups.
Further, the surgical ablation in that study was performed
through a bilateral minimal thoracotomy. This approach
was necessary to accomplish a complete surgical PVI with
the use of bipolar radiofrequency delivered by the Atricure
device. The bilateral approach adds time and increases the
chances of complications. This can be avoided with differ-
ent devices such as the Estech Cobra Fusion, which is cap-
able of a complete electrical deconnection of the posterior
left atrium, delivering bipolar radiofrequency through a
single right minimally invasive approach. According to the
European Guidelines [12], bipolar radiofrequency is the
preferred source of energy for achieving a complete trans-
mural line of ablation [19]. The transmurality of the lesions
can be consistently obtained with hybrid or simultaneous
[9] and staged or sequential [10] approaches.
The hybrid simultaneous procedures have some disad-
vantages, in that they take time and do not allow a blank
period to evaluate the clinical efficacy of surgery. The
staged procedures allow a blank period of evaluation,
and two modalities of ablation (surgical and percutaneous)
may be used after a predetermined period or only in case
of recurrences.All of these procedures share the same basic princi-
ples. The posterior left atrium (the portion where many
of the sources of PeAf are located) must be electrically
separated from the base of the heart [8], with the
addition of some endocardial lines, if necessary. In our
study, we have chosen to adopt a staged approach. This
has some possible advantages, including the evaluation
of the efficacy of a monolateral minimally invasive ap-
proach by using bipolar radiofrequency. For this, we will
use the Estech Cobra Fusion system. The ablation device
encircles the posterior portion of the left atrium and al-
lows the use of bipolar radiofrequency in a controlled
protocol. Second, the procedural time is expected to be
relatively short so as to avoid any ICU stay. Third, a
blank period will allow a second percutaneous ablation
to be performed only in patients with recurrent AF,
which should reduce the total number of invasive proce-
dures necessary to control the AF.
Finally, in our opinion, this will allow us to study the
modalities of failures of the surgical approach and give
valuable information in refinement of the techniques
and devices.
Study limitations
No standard strategy is known for the percutaneous ab-
lation of PeAF. In the PCA control group of our study,
the choice of the initial technique will be left to the
treating cardiologist (PVI, CFAE ablation with or with-
out manipulation of the substrate, or rotor manipula-
tion are frequently used in combination or in staged
procedures). Insulated PVI is the least effective tech-
nique, whereas rotor modulation has been recently intro-
duced and is not widely used. Thus, we expect that the
majority of the patients in the control group will undergo
a combination of PVI and CFAE ablation. In cases of fail-
ure in the surgical group, this choice will be dictated by
the residual electrophysiological findings. This is a poten-
tial limitation of the study that may make comparison be-
tween the two groups difficult.
Trial status
At the moment of submission, the trial is recruiting
patients.
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